S new pain reliever, Arcoxia, was gentler on the stomach than an older pain reliever.
Many analysts and doctors believe Arcoxia will only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes The 7,111-patient trial that was presented at the American College of Rheumatology's annual meeting in San Antonio, and is part of the Merck's application for approval.
Buffeted by criticism, the Food and Drug Administration would appoint a director of drug safety and take other actions to assure the safety of medications it approves.
